Journal
CLINICAL IMMUNOLOGY
Volume 122, Issue 2, Pages 139-145Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2006.08.009
Keywords
rituximab; B lymphocytes; transitional B cells; lymphoma
Categories
Funding
- NCI NIH HHS [CA-102216] Funding Source: Medline
- NIAID NIH HHS [R01 AI049660-01A1, AI56390] Funding Source: Medline
- NIAMS NIH HHS [K08AR048303] Funding Source: Medline
Ask authors/readers for more resources
The long-term immunologic effects of B cell depletion with rituximab and the characteristics of the reconstituting B cell pool in lymphoma patients are not well defined, despite the widespread usage of this therapy. Here we report that during the B cell reconstitution phase a majority of the peripheral blood B cells have an immature transitional phenotype (47.8% +/- 25.2% vs. 4.4% +/- 2.4% for normal controls, p < 0.0001), similar to what has been described during the original ontogeny of the immune system and following bone marrow transplantation. Moreover, the recovery of the CD27+ memory B cell pool was delayed compared to normal B cell ontogeny, remaining below normal controls at 1 year post-rituximab (4.4% +/- 3% vs. 31% +/- 7%, p < 0.0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment. (c) 2006 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available